Q2 2026 brought nine FDA 510(k) clearances for aesthetic devices—the highest single-quarter volume in recent memory—plus significant corporate activity that could reshape support and pricing for established platforms. For practice owners evaluating new equipment, this quarter offers both opportunity and caution: more cleared alternatives mean competitive pricing pressure, but also uncertainty around legacy systems during ownership transitions.
FDA Activity — Aesthetic Devices
Monthly 510(k) clearances versus device & drug recalls.
Nine 510(k) Clearances: What They Mean
All nine devices received Substantially Equivalent determinations, meaning they cleared via the streamlined 510(k) pathway rather than full PMA review. This matters: it signals lower regulatory risk for the manufacturer but does not guarantee clinical superiority or long-term support. The clearances span:
- Intense Pulsed Light (IPL): Sanhe LEFIS Electronics' device (product code ONF)
- Laser resurfacing platforms: LumiGlam (Beijing Sano), LASEmaR 1500 (Eufoton), and MILAN (Lumenis)
- Radiofrequency/combo systems: Veineo (F Care Systems), VIVA combo RF (Starmed)
- LED light therapy: CurrentBody Skin mask (The Beauty Tech Group)
For buyers, this means the market is crowded. Substantially Equivalent clearances often indicate predicate devices already exist—so you're choosing among proven modalities, not breakthrough technology. Prioritize vendor stability, training infrastructure, and service networks over novelty.
LED and Light-Based Devices Gain Traction
The CurrentBody Skin LED Multi Light Therapy Mask (MK-110D) is notable as the only non-laser, non-RF device in this quarter's batch. LED light therapy continues to gain FDA traction, reflecting both consumer demand and lower barriers to entry for manufacturers. For practices, LED devices offer:
- Lower capital cost than laser or RF platforms
- Minimal downtime and patient comfort
- Broad appeal to wellness-focused clientele
However, clinical efficacy claims remain modest compared to ablative or fractional laser. If your practice is considering LED as an entry point or adjunct to existing services, verify training requirements and realistic patient expectations upfront. LED works best as a complementary modality, not a standalone revenue driver.
Laser and RF Platforms Dominate Clearances
Six of nine clearances involve laser resurfacing or radiofrequency/combination systems—the workhorse categories for aesthetic practices. These include established brands (Lumenis' MILAN) alongside newer entrants (Beijing Sano, Eufoton, Starmed). All are 510(k) clears, meaning they reference existing predicate devices.
Key consideration: Substantially Equivalent clearances do not require head-to-head clinical trials against competitors. A new RF system may be cleared based on similarity to a 10-year-old predicate, not proof it outperforms current market leaders. Before investing, request independent clinical data, not just FDA clearance letters. Ask vendors about peer-reviewed publications, case studies from comparable practices, and realistic ROI timelines.
Bausch Health's Corporate Uncertainty Clouds Solta Support
Three SEC 8-K filings from Bausch Health (March, April, May 2026) signal material corporate events—likely spin-off or M&A activity involving Solta Medical, which owns Thermage, Fraxel, and Clear+Brilliant. These are flagship platforms in many practices' arsenals.
What this means for owners:
- Support and service may be disrupted during transition
- Pricing and warranty terms could shift post-restructuring
- Software updates and training timelines are uncertain
- Resale value of existing Solta equipment may fluctuate
If you own Solta devices, monitor Bausch Health announcements closely. If you're considering a Solta purchase, request written commitments on post-transaction support. New ownership often means renegotiated service agreements—sometimes favorable, sometimes not.
Clinical Trial Signals: One Active, One Terminated
Two aesthetic laser skin trials are active this quarter: Bausch Health's Phase 4 study on skin resurfacing effectiveness (ACTIVE_NOT_RECRUITING) and Erchonia's evaluation of laser for skin laxity (TERMINATED). The Erchonia termination is worth noting—it suggests either recruitment challenges, efficacy concerns, or strategic pivot.
For practice owners: Terminated trials don't invalidate a device's FDA clearance, but they may signal limited clinical differentiation or market traction. Conversely, active Phase 4 studies (post-market surveillance) indicate ongoing manufacturer investment in evidence. When evaluating devices, ask: Is the vendor funding post-market research? Are they publishing outcomes? Active clinical engagement often correlates with long-term platform stability.
Buying Strategy for Q2 2026 Clearances
With nine new clearances and market consolidation underway, practice owners face competing pressures: opportunity (more options, potential price competition) and risk (vendor stability, support continuity).
Recommended approach:
- Prioritize established brands with proven service networks over new entrants, unless pricing is dramatically lower
- Request 3–5 year support commitments in writing before purchase
- Verify training and parts availability in your region
- Avoid sole-source dependencies on platforms with uncertain ownership (e.g., Solta, pending restructuring)
- Benchmark clinical outcomes against your current systems, not just FDA clearance status
- Negotiate service terms during corporate transitions—vendors are often flexible when ownership is in flux
Q2's high clearance volume is good for competition but demands due diligence. Don't let novelty drive purchasing; stability and ROI should.
Bottom line
Nine 510(k) clearances and Bausch Health's restructuring create a buyer's market—but only for practices that prioritize vendor stability and clinical evidence over clearance volume.